§483.20(f)(5) Resident-identifiable information. (i) A facility may not release information that is resident-identifiable to the public. (ii) The facility may release information that is resident-identifiable to an agent only in accordance with a contract under which the agent agrees not to use or disclose the information except to the extent the facility itself is permitted to do so.
§483.70(h) Medical records. §483.70(h)(1) In accordance with accepted professional standards and practices, the facility must maintain medical records on each resident that are- (i) Complete; (ii) Accurately documented; (iii) Readily accessible; and (iv) Systematically organized
§483.70(h)(2) The facility must keep confidential all information contained in the resident's records, regardless of the form or storage method of the records, except when release is- (i) To the individual, or their resident representative where permitted by applicable law; (ii) Required by Law; (iii) For treatment, payment, or health care operations, as permitted by and in compliance with 45 CFR 164.506; (iv) For public health activities, reporting of abuse, neglect, or domestic violence, health oversight activities, judicial and administrative proceedings, law enforcement purposes, organ donation purposes, research purposes, or to coroners, medical examiners, funeral directors, and to avert a serious threat to health or safety as permitted by and in compliance with 45 CFR 164.512.
§483.70(h)(3) The facility must safeguard medical record information against loss, destruction, or unauthorized use.
§483.70(h)(4) Medical records must be retained for- (i) The period of time required by State law; or (ii) Five years from the date of discharge when there is no requirement in State law; or (iii) For a minor, 3 years after a resident reaches legal age under State law.
§483.70(h)(5) The medical record must contain- (i) Sufficient information to identify the resident; (ii) A record of the resident's assessments; (iii) The comprehensive plan of care and services provided; (iv) The results of any preadmission screening and resident review evaluations and determinations conducted by the State; (v) Physician's, nurse's, and other licensed professional's progress notes; and (vi) Laboratory, radiology and other diagnostic services reports as required under §483.50.
|
Observations:
Based on review of facility policy, clinical records and staff interviews, it was determined that the facility failed to document delay in treatment as recommended by consult for skin infection for one of eight residents (Resident R83) failed to document skin assessments after diagnosis of fungal infection for one of eight residents (Resident R93) and failed to document assessments while administering an opioid (Resident 112) for pain/air hunger for one of eight residents.
Findings include: Review of facility policy, "Charting and Documentation" dated 1/20/26, indicated all services provided to the resident, progress toward the care plan goals, or any changes in the resident's medical, physical, functional or psychosocial condition shall be documented in the resident's medical record. The medical record should facilitate communication between the interdisciplinary team regarding the resident's condition and response to care. Documentation in the medical record may be electronic, manual or a combination. The following information is to be documented in the resident's medical record: objective observations, medications administered, treatments or services performed, changes in resident's condition, events, incidents or accidents involving the resident, and progress toward or changes in the car plan goal or objectives.
Review of facility policy "Administering Medications" dated 1/20/26, indicated medications are administered in a safe and timely manner, and as prescribed. The director of nursing services supervises and directs all personnel who are administering medications and/or have related services. If a dosage is believed to be inappropriate or excessive for a resident, or a medication has been identified as having potential adverse consequences for the resident or is suspected of being associated with adverse consequences, the person preparing or administering the medication will contact the prescriber, the resident's attending physician or the facility's medical director to discuss the concerns.
Review of facility policy "Administering Pain Medication" reviewed 1/20/26, indicated to administer pain medications as ordered. If there are signs of serious adverse consequences related to narcotic (opioid) analgesics (including somnolence [state of strong or persistent drowsiness or a heavy desire to sleep during normal waking hours], delirium [change in brain function that causes severe confusion, trouble focusing, and rapid shifts in awareness], respiratory depression [breathing becomes too slow or too shallow to keep proper oxygen and carbon dioxide levels in the body], notify the practitioner prior to administering. Report other information in accordance with facility policy and professional standards of practice.
The Kaiser Permanente 0-to-10 pain scale uses numbers from 0 (zero) to 10 (ten) to help measure and share your level of discomfort with your care team. 0 (zero): no pain 1 (one) to 3 (three) = mild: annoying or noticeable pain that does not stop you from doing normal daily tasks. 4 (four) to 6 (six) = moderate: distracting pain that begins to get in the way of your activities and makes it hard to concentrate. 7 (seven) to 10 (ten) = severe: strong to worst possible pain that keeps you from doing normal activities, talking, or functioning.
Review of the clinical record indicated Resident R83 was admitted to the facility on 4/7/25.
Review of the Minimum Data Set (MDS-a periodic assessment of resident care needs) dated 7/2/26, included diagnoses of hypertension (high blood pressure), anxiety (natural response to stress or a perceived which can become excessive and impaired daily living), adult failure to thrive (multi-factor syndrome of physical, mental, and functional decline most common in older adults).
Review of Resident R83's care plan initiated on 4/8/25, revised on 5/19/26 and 6/9/26, for skin integrity indicated to remain free from skin breakdown daily through next review. Resident R83 will have weekly skin assessment to be performed during regularly scheduled bath/shower per facility policy. Administer treatments as ordered and monitor effectiveness. Assess/record/monitor wound healing per facility policy. Inform resident of any new skin breakdown. Revision from 6/9/26, indicated Resident R83 will have no complications from rash through the review date. Resident R83 will avoid scratching and keep hands and body parts from excessive moisture, increase out of bed activity as tolerated, and monitor skin rashes for increased spread or signs of infection.
Review of Resident R83's clinical record revealed a consult with a dermatologist on 8/12/26, resident returned with recommendations for Clindamycin 1% Ointment to be applied to the back once a day after bathing. In review of orders the order was not placed until 8/20/26, no documentation noted to state that consult paperwork was reviewed and recommendation was related to facility physician.
Review of the clinical record indicated Resident R93 was admitted to the facility on 4/20/25.
Review of the MDS dated 8/3/26, included diagnoses of hypertension, muscle weakness, diabetes (a metabolic disorder ub which the body has high sugar levels for prolonged periods of time), end-stage renal disease (final permanent stage of chronic kidney disease requiring either dialysis or kidney transplant).
Review of Resident R93's care plan initiated on 4/20/25, revised on 2/12/26, for skin integrity indicated Resident R93 will remain free from skin breakdown daily through next review date. Resident R93 will have house barrier cream to buttocks, moisturizing lotions with AM and PM care, encourage/remind/assist to turn/reposition as needed or required, support surface to bed: pressure reducing mattress, support surface to chair, pressure reducing cushion for wheelchair. On 6/4/26, care plan initiated for actual impairment to skin integrity of the axilla r/t fungal rash with potential for complications. Resident R93 will have treatment applied per order, avoid scratching and keep hands and body parts from excessive moisture, and encourage good nutrition and hydration in order to promote healthier skin. On 6/7/26, care plan initiated for Resident R93 has a fungal rash under bilateral breasts with an antifungal cream. Goal is to have rash healed by review date. Resident R93 will avoid scratching and keep hands and body parts from excessive moisture, monitor skin rashes for increased spread or signs of infection, seek medical attention if skin becomes bloody or infected.
Review of the clinical record revealed resident seen on 5/23/26 for "Right axilla with red fungal rash. [Medical] on-call notified and new order received. Resident made aware of new orders." Further review of the clinical record-order summary revealed no new orders for this date range, care plan not updated for thirteen days regarding new issue, no further documentation regarding skin assessments after initial date of diagnosis.
Review of the clinical record indicated Resident R112 was admitted to the facility on 7/2/26, with diagnoses that included urinary tract infection (UTI), anxiety, and difficulty in walking.
Review of physician orders revealed the following: -On 7/5/26, Lorazepam (Ativan prescription benzodiazepine used to treat anxiety disorders) one mg (milligram), give one (1) tablet by mouth one time only for agitation. -On 7/5/26, Morphine Sulfate (strong opioid pain medication) oral solution 20mg/ml (milliliter), give 0.5 ml by mouth every one (1) hour as needed for moderate to severe pain/air hunger.
Review of the vital signs, and Medication Administration Record (MAR) for July 2026, revealed Resident R112 received the following: -On 7/5/26, at 2:04 a.m. Vital signs (VS): Blood pressure (BP) was 128/98; Pulse (P) 73; Oxygen (O2) level 98%; Respirations (R)18; Pain level 4/10. -On 7/5/26, at 11:18 a.m. Pain level 4/10. -On 7/5/26, at 2:03 p.m. VS: BP 118/87; P 72; O2 98%; R 18; Pain level 6/10. -On 7/5/26, at 4:50 p.m. Pain level 5/10. -On 7/5/26, at 5:25 p.m. Morphine Sulfate 20 mg/ml, 0.5 ml. -On 7/5/26, at 6:35 p.m. Morphine Sulfate 20 mg/ml, 0.5ml. -On 7/5/26, at 7:35 p.m. Morphine Sulfate 20 mg/ml, 0.5 ml. -On 7/5/26, at 8:35 p.m. Morphine Sulfate 20 mg/ml, 0.5 ml. -On 7/5/26, at 9:21 p.m. Lorazepam one mg tablet, one tablet was given. -On 7/5/26, at 9:35 p.m. Morphine Sulfate 20 mg/ml, 0.5 ml. -On 7/5/26, at 10:09 p.m. VS: BP 105/66; O2 96%; R 16; pain level 5/10. -On 7/5/26, at 11:37 p.m. Morphine Sulfate 20 mg/ml, 0.5 ml. BP 102/68: P 64; R 20; O2 94%; Pain level 3/10. -On 7/6/26, at 1:51 a.m. Morphine Sulfate 20 mg/ml, 0.5 ml. -On 7/6/26, at 6:17 a.m. Morphine Sulfate 20 mg/ml, 0.5 ml. -On 7/6/26, at 6:50 a.m. VS: BP 84/68; P 112; R 14; O2 88%. -On 7/6/26, at 9:55 a.m. VS: BP 85/58; P 58; R 24; O2 91%; pain level 0/10. -On 7/6/26, at 10:55 a.m. pain level 0/10. -On 7/6/26, at 5:21 p.m. Morphine Sulfate 20 mg/ml, 0.5 ml. -On 7/6/26, at 5:39 p.m. pain level 0/10. -On 7/6/26, at 8:21 p.m. Morphine Sulfate 20 mg/ml, 0.5 ml.
Review of the progress notes failed to reveal an assessment of Resident R112's condition, side effects of medications administered, and/or behaviors observed (agitation, respiratory distress, air hunger) relating to Resident R112 receiving pain medication and lorazepam. Further review of a progress note dated 7/7/26, at 1:45 a.m. indicated Resident R112 ceased to breathe at 12:22 a.m.
During an interview on 8/26/26, at approximately 9:45 a.m. the Director of Nursing confirmed that the clinical record failed to reveal further skin assessments, follow-up care, review of orders, and review of consultation documentation for Resident R83 and R93.
During an interview on 8/27/26, at 11:15 a.m. the Director of Nursing confirmed the medical record failed to include documentation and assessments for Resident R112 receiving morphine sulfate and lorazepam.
28 Pa. Code 201.18 (b)(1) Management 28 Pa. Code 211.10 (c)(d) Resident care policies 28 Pa. Code 211.12 (d)(1)(2)(3)(5) Nursing services
| | Plan of Correction - To be completed: 10/08/2026
Resident R83 and R93 have orders in place per MD. R112 discharged 7/7/26. whole house audit of documentation and assessment for pain medication, review consults upon return from appointments related to skin, skin assessments completed for an identified skin infection. DON or designee will educate licensed nurses on charting and documentation, administering pain medications, administering medication policies and pain and skin assessment completion and the process of reviewing consultations upon return from an appointment. DON or designee will audit 5 residents for 2 weeks to ensure that documentation and assessments related to pain medication, skin assessment complete when a skin infection is identified, recommendation reviewed and order placed upon return from an appointment is reflected in the clinical record. Audit will be taken to QAPI for review.
|
|